Zacks: Merck will benefit from Schering deal

Merck needs the Schering-Plough deal, a new Zacks analyst report states. Schering's still-on-patent drugs will help make up Merck's shortfalls as its branded meds start to face generic competition. Plus, Zacks sees "immediate synergies"--read cost-cutting opportunities--for the two companies' cholesterol drugs partnership. Report

Suggested Articles

Mylan and Pfizer's Upjohn have a name for their pending merger: Viatris. Heard that before? So has Mylan, which owns a subsidiary with the same name.

Intercept presented a data analysis that found treatment with Ocaliva led to "early and consistent improvements" in a range of noninvasive tests.

Days before Amarin faces a pivotal FDA vote on its Vascepa expansion, advisors are set to scrutinize the placebo used in its pivotal outcomes trial.